Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CAR-T
Biotech
Tempest strikes all-stock deal for Factor’s CAR-T pipeline, CEO
After seeking strategic alternatives, Tempest is inking an all-stock transaction for four of Factor's CAR-T candidates.
Gabrielle Masson
Nov 19, 2025 12:22pm
'Gilead wants us to rebuild': Why Galapagos can't go extinct
Nov 19, 2025 7:50am
Fierce Pharma
J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T
Nov 12, 2025 11:36am
Lyell signs deal for phase 1-stage colorectal cancer CAR-T
Nov 10, 2025 9:45am
Sana, CAMP4 ditch clinical-stage assets for preclinical hopefuls
Nov 7, 2025 8:13am
Kyverna links CAR-T to autoimmune improvements in small trial
Oct 29, 2025 10:00am
